ZGNX Zogenix, Inc.

10.70
0  0%
Previous Close 10.75
Open 10.80
Price To book 2.21
Market Cap 265.50M
Shares 24,813,000
Volume 87,062
Short Ratio 13.64
Av. Daily Volume 269,765

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2017.
ZX008
Lennox-Gastaut syndrome
Approved July 16, 2009.
Sumavel
Migraine
Phase 3 initiation of efficacy portion announced February 13, 2017.
ZX008 - Study 1504
Dravet syndrom
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Approved October 25, 2013.
Zohydro ER
Moderate to severe pain
Phase 3 data due 3Q 2017.
ZX008 - (Study 1)
Dravet syndrom
Approved January 30, 2015.
Abuse deterrent formulations of Zohydro ER
Moderate to severe pain

Latest News

  1. ETFs with exposure to Zogenix, Inc. : April 17, 2017
  2. Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  3. Zogenix, Inc. :ZGNX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  4. Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference
  5. Zogenix reports 4Q loss
  6. Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
  7. Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9
  8. Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome
  9. Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference
  10. Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome
  11. Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
  12. Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome
  13. Blog Coverage Novartis Announced Buyback of Shares Worth $5 Billion; Considers Strategic Options for Alcon Division
  14. ETFs with exposure to Zogenix, Inc. : December 21, 2016
  15. Is Foamix Pharmaceuticals Ltd (FOMX) Going to Burn These Hedge Funds?
  16. Hedge Funds Are Piling Back Into Zogenix, Inc. (ZGNX): Should You Follow?
  17. Earnings Estimates Moving Higher for Zogenix (ZGNX): Time to Buy?
  18. Moving Average Crossover Alert: Zogenix (ZGNX)